Xu Y - Search Results

1

The circadian clock modulates enamel development.

Lacruz RS, Hacia JG, Bromage TG, Boyde A, Lei Y, Xu Y, Miller JD, Paine ML, Snead ML. Lacruz RS, et al. Among authors: xu y. J Biol Rhythms. 2012 Jun;27(3):237-45. doi: 10.1177/0748730412442830. J Biol Rhythms. 2012. PMID: 22653892 Free PMC article.

2

CCAAT/enhancer-binding protein delta (C/EBPdelta) maintains amelogenin expression in the absence of C/EBPalpha in vivo.

Xu Y, Zhou YL, Gonzalez FJ, Snead ML. Xu Y, et al. J Biol Chem. 2007 Oct 12;282(41):29882-9. doi: 10.1074/jbc.M702097200. Epub 2007 Aug 17. J Biol Chem. 2007. PMID: 17704518 Free PMC article.

3

NF-Y and CCAAT/enhancer-binding protein alpha synergistically activate the mouse amelogenin gene.

Xu Y, Zhou YL, Luo W, Zhu QS, Levy D, MacDougald OA, Snead ML. Xu Y, et al. J Biol Chem. 2006 Jun 9;281(23):16090-8. doi: 10.1074/jbc.M510514200. Epub 2006 Apr 4. J Biol Chem. 2006. PMID: 16595692 Free article.

4

Transcription factor sumoylation and factor YY1 serve to modulate mouse amelogenin gene expression.

Xu Y, Zhou YL, Ann DK, MacDougald OA, Shum L, Snead ML. Xu Y, et al. Eur J Oral Sci. 2006 May;114 Suppl 1:169-77; discussion 201-2, 381. doi: 10.1111/j.1600-0722.2006.00319.x. Eur J Oral Sci. 2006. PMID: 16674681

5

Physical dissection of the CCAAT/enhancer-binding protein alpha in regulating the mouse amelogenin gene.

Xu Y, Zhou YL, Erickson RL, Macdougald OA, Snead ML. Xu Y, et al. Biochem Biophys Res Commun. 2007 Mar 2;354(1):56-61. doi: 10.1016/j.bbrc.2006.12.182. Epub 2007 Jan 2. Biochem Biophys Res Commun. 2007. PMID: 17210130 Free PMC article.

6

Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo.

Xu T, Xu Y, Liao CP, Lau R, Goldkorn A. Xu T, et al. Among authors: xu y. Mol Cancer Ther. 2010 Feb;9(2):438-49. doi: 10.1158/1535-7163.MCT-09-0682. Epub 2010 Feb 2. Mol Cancer Ther. 2010. PMID: 20124445 Free PMC article.

7

Cancer transcriptomic profiling from rapidly enriched circulating tumor cells.

Morrison GJ, Cunha AT, Jojo N, Xu Y, Xu Y, Kwok E, Robinson P, Dorff T, Quinn D, Carpten J, Manojlovic Z, Goldkorn A. Morrison GJ, et al. Among authors: xu y. Int J Cancer. 2020 May 15;146(10):2845-2854. doi: 10.1002/ijc.32915. Epub 2020 Feb 27. Int J Cancer. 2020. PMID: 32037533 Free PMC article.

8

An approach to gene-specific transcription inhibition using oligonucleotides complementary to the template strand of the open complex.

Milne L, Xu Y, Perrin DM, Sigman DS. Milne L, et al. Among authors: xu y. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3136-41. doi: 10.1073/pnas.97.7.3136. Proc Natl Acad Sci U S A. 2000. PMID: 10716709 Free PMC article.

9

Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.

He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A. He K, et al. Among authors: xu t, xu y. Int J Cancer. 2014 Jan 1;134(1):43-54. doi: 10.1002/ijc.28341. Epub 2013 Aug 5. Int J Cancer. 2014. PMID: 23784558 Free article.

10

Synthesis and testing of new modified nucleosides.

Jung ME, Nichols CJ, Kretschik O, Xu Y. Jung ME, et al. Among authors: xu y. Nucleosides Nucleotides. 1999 Apr-May;18(4-5):541-6. doi: 10.1080/15257779908041490. Nucleosides Nucleotides. 1999. PMID: 10432645

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67,805 results

Search Page